Published in Oncology Business Week, December 18th, 2005
Adventrx reported a net loss of $3.5 million, or $0.06 per share, for the third quarter of 2005, compared with a net loss of $2.1 million, or $0.04 per share, for the third quarter of 2004.
"In the third quarter Adventrx experienced increased visibility to the investment community with the company's selection to the new Russell Microcap Index and with a $20 million private equity placement led by Carl Icahn," said Evan M. Levine, Adventrx president and chief executive officer. "We increased the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.